These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 30885429)

  • 1. Pharmacological Modulation of the STING Pathway for Cancer Immunotherapy.
    Berger G; Marloye M; Lawler SE
    Trends Mol Med; 2019 May; 25(5):412-427. PubMed ID: 30885429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STING pathway agonism as a cancer therapeutic.
    Flood BA; Higgs EF; Li S; Luke JJ; Gajewski TF
    Immunol Rev; 2019 Jul; 290(1):24-38. PubMed ID: 31355488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current patent and clinical status of stimulator of interferon genes (STING) agonists for cancer immunotherapy.
    Marloye M; Lawler SE; Berger G
    Pharm Pat Anal; 2019 Jul; 8(4):87-90. PubMed ID: 31354104
    [No Abstract]   [Full Text] [Related]  

  • 4. cGAS-STING signaling in cancer immunity and immunotherapy.
    Du H; Xu T; Cui M
    Biomed Pharmacother; 2021 Jan; 133():110972. PubMed ID: 33254021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. cGAS-STING and Cancer: Dichotomous Roles in Tumor Immunity and Development.
    Ng KW; Marshall EA; Bell JC; Lam WL
    Trends Immunol; 2018 Jan; 39(1):44-54. PubMed ID: 28830732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insight into the dichotomous regulation of STING activation in immunotherapy.
    Hu Z; Yang Y; Fang L; Zhou J; Zhang H
    Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):126-137. PubMed ID: 33618600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer.
    Corrales L; Gajewski TF
    Clin Cancer Res; 2015 Nov; 21(21):4774-9. PubMed ID: 26373573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. cGAS/STING Pathway in Cancer: Jekyll and Hyde Story of Cancer Immune Response.
    Bose D
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29156566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges faced when identifying patients for combination immunotherapy.
    Ernstoff MS; Gandhi S; Pandey M; Puzanov I; Grivas P; Montero A; Velcheti V; Turk MJ; Diaz-Montero CM; Lewis LD; Morrison C
    Future Oncol; 2017 Aug; 13(18):1607-1618. PubMed ID: 28835114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy.
    Queirolo P; Boutros A; Tanda E; Spagnolo F; Quaglino P
    Semin Cancer Biol; 2019 Dec; 59():290-297. PubMed ID: 31430555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer.
    Lee EK; Konstantinopoulos PA
    Trends Cancer; 2019 Sep; 5(9):524-528. PubMed ID: 31474356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
    Maxwell R; Jackson CM; Lim M
    Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy.
    Dai E; Zhu Z; Wahed S; Qu Z; Storkus WJ; Guo ZS
    Mol Cancer; 2021 Dec; 20(1):171. PubMed ID: 34930302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance for immunoregulation for long-term cancer control.
    Fusi A; Dalgleish A
    Future Oncol; 2017 Aug; 13(18):1619-1632. PubMed ID: 28776411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
    Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
    J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
    Xia Y; Medeiros LJ; Young KH
    Blood Rev; 2016 May; 30(3):189-200. PubMed ID: 26699946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired resistance to cancer immunotherapy.
    Draghi A; Chamberlain CA; Furness A; Donia M
    Semin Immunopathol; 2019 Jan; 41(1):31-40. PubMed ID: 29968044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of the PD-1 Pathway in Tumor Therapy.
    LaFleur MW; Muroyama Y; Drake CG; Sharpe AH
    J Immunol; 2018 Jan; 200(2):375-383. PubMed ID: 29311378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of Stimulation of Interferon Genes (STING) Signal and Cancer Immunotherapy.
    Luo K; Li N; Ye W; Gao H; Luo X; Cheng B
    Molecules; 2022 Jul; 27(14):. PubMed ID: 35889509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STING Signaling in Cancer Cells: Important or Not?
    Sokolowska O; Nowis D
    Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):125-132. PubMed ID: 28748479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.